The company posted better than expected results for 1QFY2017 with sales at Rs366cr V/s Rs350cr expected and V/s Rs400cr in 1QFY2016, a yoy de-growth of 8.5%. CRAMS (Rs258cr) posted a growth of 2.3% yoy and the Market Molecules other segment (Rs108cr) posted de-growth of 26.9% yoy. On the operating front, the EBITDA margin came in at 25.3%..